AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04742101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S65487 and azacitidine
Description: Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
Study NCT05161897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition Therapy
Description: Explained in arm/group description.
Study NCT04223817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7.0 T RMI
Description: Single 7.0 Tesla MRI of both hands in the same time
Study NCT05252897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic necrosectomy with step up approach
Description: Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
Study NCT05252897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic necrosectomy with direct approach
Description: Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
Study NCT05930119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: 300 mg HMPL-453
Study NCT05930119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20 mg of rabeprazole will be administered by mouth once daily.
Study NCT04772872 — intervention group
Intervention type: OTHER
Intervention: Assessment by Brazelton neonatal behavior for group A,Band C
Description: * Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams.
Study NCT06048302 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Obicetrapib
Description: 1 single dose of obicetrapib
Study NCT06048302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib
Description: 1 single dose of obicetrapib
Study NCT05411718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Given by PO
Study NCT05411718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Given by PO
Study NCT05489341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging with Follow-Up
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
Study NCT05489341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
Study NCT05672329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
Study NCT05672329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
Study NCT05672329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
Study NCT05672329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
Study NCT05691894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPI
Description: Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
Study NCT05691894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
Study NCT05260671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with cetuximab
Description: PD-1 antibody combined with EGFR inhibitors, biweekly
Study NCT04687657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord blood
Description: During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
Study NCT05514769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
Description: The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
Study NCT05514769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
Description: The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
Study NCT04662567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: compare the postoperative pain 1 hour and \~24h post surgery
Study NCT05572008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein nutrition in paediatric Crohn's disease
Description: All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17
Study NCT05572008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein nutrition in paediatric Crohn's disease
Description: All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17
Study NCT05917912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline Hydrochloride
Description: hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Study NCT05917912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Study NCT06093906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Processes and Transition to Health
Description: See arm/group description for details regarding this intervention
Study NCT06093906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: See arm/group description for details regarding this intervention
Study NCT05480683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT exam
Description: Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
Study NCT06394570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
Study NCT03301558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose sodium bicarbonate
Description: 1500 mg sodium bicarbonate
Study NCT03301558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose sodium bicarbonate
Description: 3000 mg sodium bicarbonate
Study NCT06288555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ipswich touch test
Description: Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses.
Study NCT05625698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MagTrace only
Description: see information in arm descriptions
Study NCT05625698 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MagTrace and Magseed
Description: see information in arm descriptions
Study NCT04925349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: blood sample collection
Study NCT04945187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led consultations based on electronic patient-reported outcomes
Description: The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
Study NCT05055843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo 3D MRI
Study NCT05800600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Study NCT04811703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined PIPAC / IV chemotherapy treatment
Description: Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
Study NCT06553092 — intervention group
Intervention type: OTHER
Intervention: Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey
Description: The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
Study NCT05097820 — intervention group
Intervention type: DEVICE
Intervention: Placement of testicular prosthesis
Description: The surgical implantation of one or two testicular prostheses on request of the patient
Study NCT04854018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Intravenous or intraparenchymal injection
Study NCT05490186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
Study NCT05490186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
Study NCT05740488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg, po, qd
Study NCT05740488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Sr
Description: 100\~150MBq(based on weight), iv, q90d
Study NCT05740488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: sc, 3.6mg, q30d or 10.8mg, q90d
Study NCT06279858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
Study NCT06084832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood microsampling
Description: blood microsampling for the measure of Phosphatidylethanol
Study NCT06084832 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood microsampling
Description: blood microsampling for the measure of Phosphatidylethanol
Study NCT06072911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercise program
Description: General exercises will be prescribed along with a specialized pelvic floor program
Study NCT06072911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program
Description: General exercises will be prescribed along with a specialized pelvic floor program
Study NCT06072911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General exercise
Description: A general progressive resistance exercise program
Study NCT06072911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Counseling
Description: Advice on increasing physical activity
Study NCT05924061 — intervention group
Intervention type: OTHER
Intervention: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
Description: The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
Study NCT05608603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Portable cardiac monitor CardioQvark
Description: Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.
Study NCT05608603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory stress test
Description: Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.
Study NCT05608603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer
Description: The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
Study NCT05208905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esprit BTK Device
Description: Participants will receive Esprit BTK Device
Study NCT05323136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for Injection
Description: single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
Study NCT06412510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy
Study NCT06005935 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
Study NCT06403007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonics plus morphology
Description: This intervention trains teachers to teach phonics plus morphology to at-risk poor readers
Study NCT06403007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonics plus set-for-variability
Description: This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
Study NCT04921943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
Study NCT04933773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifact - knocking
Description: 60 seconds motion artifact simulation - knocking with sensors
Study NCT04921943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Standard of care
Study NCT04921943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Standard of care
Study NCT04921943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Standard of care